Combining clinicopathological predictors and molecular biomarkers in the oncogenic K-RAS/Ki67/HIF-1α pathway to predict survival in resectable pancreatic cancer

British Journal of Cancer

Volumn 112, Issue 3, 2015, Pages 514-522

  Qin, R ^a   Smyrk, T C ^a   Reed, N R ^a   Schmidt, R L ^b,c   Schnelldorfer, T ^a   Chari, S T ^a   Petersen, G M ^a   Tang, A H ^a,b,d  

^a MAYO CLINIC CANCER CENTER   (United States)

^b MAYO GRADUATE SCHOOL   (United States)

^c Upper Iowa University   (United States)

^d EASTERN VIRGINIA MEDICAL SCHOOL   (United States)

Author keywords

clinicopathological predictors; hypoxia; oncogenic K RAS signalling pathway; pancreatic cancer; prognostic biomarkers

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; HYPOXIA INDUCIBLE FACTOR 1ALPHA; K RAS PROTEIN; KI 67 ANTIGEN; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN; SEVEN IN ABSENTIA HOMOLOG; UNCLASSIFIED DRUG;

ARTICLE; CANCER PATIENT; CANCER SURGERY; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; HYPOXIA; IMMUNOHISTOCHEMISTRY; LYMPH NODE; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PANCREAS CANCER; PREDICTOR VARIABLE; PRIORITY JOURNAL; STAINING; TISSUE MICROARRAY; TUMOR VOLUME;

EID: 84964284177     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2014.659     Document Type: Article

References (31)

1. Ahmed AU, Schmidt RL, Park CH, Reed NR, Hesse SE, Thomas CF Molina JR, Deschamps C, Yang P, Aubry MC, Tang AH (2008) Effect of disrupting seven-in-absentia homolog 2 function on lung cancer cell growth. J Natl Cancer Inst 100(22): 1606-1629.
2. Akakura N, Kobayashi M, Horiuchi I, Suzuki A, Wang J, Chen J, Niizeki H Kawamura K, Hosokawa M, Asaka M (2001) Constitutive expression of hypoxia-inducible factor-1alpha renders pancreatic cancer cells resistant to apoptosis induced by hypoxia and nutrient deprivation. Cancer Res 61(17): 6548-6554.
3. Ardito CM, Gruner BM, Takeuchi KK, Lubeseder-Martellato C Teichmann N, Mazur PK, Delgiorno KE, Carpenter ES, Halbrook CJ Hall JC, Pal D, Briel T, Herner A, Trajkovic-Arsic M, Sipos B, Liou GY Storz P, Murray NR, Threadgill DW, Sibilia M, Washington MK Wilson CL, Schmid RM, Raines EW, Crawford HC, Siveke JT (2012) EGF receptor is required for KRAS-induced pancreatic tumorigenesis. Cancer Cell 22(3): 304-317.
4. Chang Q, Jurisica I, Do T, Hedley DW (2011) Hypoxia predicts aggressive growth and spontaneous metastasis formation from orthotopically grown primary xenografts of human pancreatic cancer. Cancer Res 71(8): 3110-3120.
5. Conroy T, Desseigne F, Ychou M, Bouche O, Guimbaud R, Becouarn Y Adenis A, Raoul JL, Gourgou-Bourgade S, de la Fouchardiere C, Bennouna J Bachet JB, Khemissa-Akouz F, Pere-Verge D, Delbaldo C, Assenat E Chauffert B, Michel P, Montoto-Grillot C, Ducreux M (2011) FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 364(19): 1817-1825.
6. Costello E, Greenhalf W, Neoptolemos JP (2012) New biomarkers and targets in pancreatic cancer and their application to treatment. Nat Rev Gastroenterol Hepatol 9(8): 435-444.
7. Guillaumond F, Leca J, Olivares O, Lavaut MN, Vidal N, Berthezene P, Dusetti NJ Loncle C, Calvo E, Turrini O, Iovanna JL, Tomasini R, Vasseur S (2013) Strengthened glycolysis under hypoxia supports tumor symbiosis and hexosamine biosynthesis in pancreatic adenocarcinoma. Proc Natl Acad Sci USA 110(10): 3919-3924.
8. Heagerty PJ, Zheng Y (2005) Survival model predictive accuracy and ROC curves. Biometrics 61(1): 92-105.
9. Hidalgo M (2010) Pancreatic cancer. N Engl J Med 362(17): 1605-1617.
10. Hruban RH, Goggins M, Parsons J, Kern SE (2000) Progression model for pancreatic cancer. Clin Cancer Res 6(8): 2969-2972.
11. Javle MM, Gibbs JF, Iwata KK, Pak Y, Rutledge P, Yu J, Black JD, Tan D Khoury T (2007) Epithelial-mesenchymal transition (EMT) and activated extracellular signal-regulated kinase (p-Erk) in surgically resected pancreatic cancer. Ann Surg Oncol 14(12): 3527-3533.
12. KatzMH, Wang H, Fleming JB, Sun CC,Hwang RF,Wolff RA,VaradhacharyG Abbruzzese JL, Crane CH, Krishnan S, Vauthey JN, Abdalla EK, Lee JE Pisters PW, Evans DB (2009) Long-term survival after multidisciplinary management of resected pancreatic adenocarcinoma. Ann Surg Oncol 16(4): 836-847.
13. Kitada T, Seki S, Sakaguchi H, Sawada T, Hirakawa K, Wakasa K (2003) Clinicopathological significance of hypoxia-inducible factor-1alpha expression in human pancreatic carcinoma. Histopathology 43(6): 550-555.
14. Lebe B, Sagol O, Ulukus C, Coker A, Karademir S, Astarcioglu H, Kupelioglu A Astarcioglu I, Obuz F (2004) The importance of cyclin D1 and Ki67 expression on the biological behavior of pancreatic adenocarcinomas. Pathol Res Pract 200(5): 389-396.
15. Maitra A, Hruban RH (2008) Pancreatic cancer. Annu Rev Pathol 3: 157-188.
16. Sawyers CL (2008) The cancer biomarker problem. Nature 452(7187): 548-552.
17. Schmidt RL, Park CH, Ahmed AU, Gundelach JH, Reed NR, Cheng S Knudsen BE, Tang AH (2007) Inhibition of RAS-mediated transformation and tumorigenesis by targeting the downstream E3 ubiquitin ligase seven in absentia homologue. Cancer Res 67(24): 11798-11810.
18. Sebolt-Leopold JS, Herrera R (2004) Targeting the mitogen-activated protein kinase cascade to treat cancer. Nat Rev Cancer 4(12): 937-947.
19. Semenza GL (2003) Targeting HIF-1 for cancer therapy. Nat Rev Cancer 3(10): 721-732.
20. Shibaji T, Nagao M, Ikeda N, Kanehiro H, Hisanaga M, Ko S, Fukumoto A Nakajima Y (2003) Prognostic significance of HIF-1 alpha overexpression in human pancreatic cancer. Anticancer Res 23(6C): 4721-4727.
21. Siegel R, Naishadham D, Jemal A (2013) Cancer statistics, 2013. CA Cancer J Clin 63(1): 11-30.
22. Sohn TA, Yeo CJ, Cameron JL, Koniaris L, Kaushal S, Abrams RA, Sauter PK Coleman J, Hruban RH, Lillemoe KD (2000) Resected adenocarcinoma of the pancreas-616 patients: results, outcomes, and prognostic indicators. J Gastrointest Surg 4(6): 567-579.
23. Spivak-Kroizman TR, Hostetter G, Posner R, Aziz M, Hu C, Demeure MJ Von Hoff D, Hingorani SR, Palculict TB, Izzo J, Kiriakova GM Abdelmelek M, Bartholomeusz G, James BP, Powis G (2013) Hypoxia triggers hedgehog-mediated tumor-stromal interactions in pancreatic cancer. Cancer Res 73(11): 3235-3247.
24. Stanton KJ, Sidner RA, Miller GA, Cummings OW, Schmidt CM, Howard TJ Wiebke EA (2003) Analysis of Ki-67 antigen expression, DNA proliferative fraction, and survival in resected cancer of the pancreas. Am J Surg 186(5): 486-492.
25. Valle JW, Palmer D, Jackson R, Cox T, Neoptolemos JP, Ghaneh P Rawcliffe CL, Bassi C, Stocken DD, Cunningham D, OReilly D Goldstein D, Robinson BA, Karapetis C, Scarfe A, Lacaine F, Sand J Izbicki JR, Mayerle J, Dervenis C, Olah A, Butturini G, Lind PA Middleton MR, Anthoney A, Sumpter K, Carter R, Buchler MW (2014) Optimal duration and timing of adjuvant chemotherapy after definitive surgery for ductal adenocarcinoma of the pancreas: ongoing lessons from the ESPAC-3 study. J Clin Oncol 32(6): 504-512.
26. Vogelstein B, Papadopoulos N, Velculescu VE, Zhou S, Diaz Jr LA Kinzler KW (2013) Cancer genome landscapes. Science 339(6127): 1546-1558.
27. Von Hoff DD, Korn R, Mousses S (2009) Pancreatic cancer-could it be that simple? A different context of vulnerability. Cancer Cell 16(1): 7-8.
28. Wilson WR, Hay MP (2011) Targeting hypoxia in cancer therapy. Nat Rev Cancer 11(6): 393-410.
29. Winter JM, Yeo CJ, Brody JR (2013) Diagnostic, prognostic, and predictive biomarkers in pancreatic cancer. J Surg Oncol 107(1): 15-22.
30. Wolfgang CL, Herman JM, Laheru DA, Klein AP, Erdek MA, Fishman EK Hruban RH (2013) Recent progress in pancreatic cancer. CA Cancer J Clin 63(5): 318-348.
31. Zhong H, De Marzo AM, Laughner E, Lim M, Hilton DA, Zagzag D Buechler P, Isaacs WB, Semenza GL, Simons JW (1999) Overexpression of hypoxia-inducible factor 1alpha in common human cancers and their metastases. Cancer Res 59(22): 5830-5835.